A Case Report on the Palliative Role of Intraluminal Brachytherapy (IIBT) in Advanced Hilar Cholangiocarcinoma

Article Sidebar

PDF
Published: May 4, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i5-03
Keywords:
Cholangiocarcinoma, Intra Luminal Brachytherapy (ILBT), palliation, Percutaneous Transhepatic Biliary Drainage (PTBD), advanced.

Main Article Content

Dr. Shreya Chatterjee
Dept. of Radiation Oncology, Vydehi Institute of Medical Sciences, Bangalore, India
Dr Pranitha Sl
Dept. of Radiation Oncology, Vydehi Institute of Medical Sciences, Bangalore, India
Dr. Geeta SN
Dept. of Radiation Oncology, Vydehi Institute of Medical Sciences, Bangalore, India
Dr. S. Narayanan
Chief Medical Physicist and RSO, Dept. of Radiation Oncology, Vydehi Institute of Medical Sciences, Bangalore, India

Abstract

Cholangiocarcinoma (CCA) is the primary malignant tumor of bile ducts which originates from the cholangiocytes. It accounts for 10-15% of all Hepato-biliary malignancies. Hilar Cholangiocarcinoma (Klatskin tumor) is a type of  extrahepatic CCA. We present a case of 37-year-old female patient diagnosed with Hilar Cholangiocarcinoma who presented with complaints of loss of appetite since 2 months associated with generalized itching and yellowish discoloration of sclera & skin with palpable firm mass in right hypochondriac region. The patient underwent Percutaneous Transhepatic Biliary Drainage (PTBD) followed by internalization to relieve the biliary obstruction along with Intra Luminal Brachytherapy (ILBT) of 20Gy (4 fractions of 5Gy each). The patient was symptomatically better for 6 months with much alleviation of pain, jaundice and was able to continue with her daily activities. Therefore, it can be concluded by saying that ILBT is an effective modality of treatment in HCCA for alleviation of pain and maintaining patency post PTBD procedure.

Article Details

How to Cite
Dr. Shreya Chatterjee, Dr Pranitha Sl, Dr. Geeta SN, & Dr. S. Narayanan. (2023). A Case Report on the Palliative Role of Intraluminal Brachytherapy (IIBT) in Advanced Hilar Cholangiocarcinoma. International Journal of Medical Science and Clinical Research Studies, 3(05), 808–811. https://doi.org/10.47191/ijmscrs/v3-i5-03
Issue
Vol. 3 No. 05 (2023): Volume 03 Issue 05 May 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Khosla D, Zaheer S, Gupta R, Madan R, Goyal S, Kumar N, Kapoor R. Role of intraluminal brachytherapy in palliation of biliary obstruction in cholangiocarcinoma: A brief review. World J GastrointestEndosc 2022; 14(3): 106-112 [PMID: 35432743 DOI: 10.4253/wjge.v14.i3.106]

II. Goenka MK, Goenka U. Palliation: Hilar cholangiocarcinoma. World J Hepatol. 2014 Aug 27;6(8):559-69. doi: 10.4254/wjh. v6.i8.559. PMID: 25232449; PMCID: PMC4163739.

III. Romeo Obiekwe S, Suzett De La Roca N, Saric J. Cholangiocarcinoma [Internet]. Surgical Challenges in the Management of Liver Disease. IntechOpen; 2019. Available from: http://dx.doi.org/10.5772/intechopen.81326

IV. Chigurupalli, Kiran; Vashistha, Apoorv. Role of intraluminal brachytherapy as a palliative treatment modality in unresectable cholangiocarcinomas. Journal of Cancer Research and Therapeutics 17(1):p 10-12, Jan–Mar 2021. | DOI: 10.4103/jcrt.JCRT_836_19

V. Bruha R, Petrtyl J, Kubecova M, Marecek Z, Dufek V, Urbanek P, Kodadova J, Chodounsky Z. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies--the question of long-term palliation. Hepatogastroenterology. 2001;48:631–637.

VI. Chen Y, Wang XL, Yan ZP, Cheng JM, Wang JH, Gong GQ, Qian S, Luo JJ, Liu QX. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol. 2004;10:3506–3510.

VII. Aggarwal R, Patel FD, Kapoor R, Kang M, Kumar P, Chander Sharma S. Evaluation of high-dose-rate intraluminal brachytherapy by percutaneous transhepatic biliary drainage in the palliative management of malignant biliary obstruction-

-a pilot study. Brachytherapy.2013;12:162–170.